Pulling SEC filings + quote and writing the call…

DBV Technologies S.A.
Next earnings Jul 27, 2026 · consensus $-0.10 EPS, $1.40M rev
Last earnings +3.4% on 2026-04-30
Pre-revenue biotech with one shot on goal (Viaskin Peanut) priced at $4.75B on $5.6M sales — speculative, not investable on fundamentals.
DBVT is a late-stage specialty biopharma whose entire equity story hinges on one asset: the Viaskin Peanut epicutaneous patch for pediatric peanut allergy. The 10-K MD&A is explicit that 2026's focus is 'commercialization and laying the groundwork to transform the lives of children living with peanut allergy' — meaning the company is still pre-approval, and the FY2025 revenue line of $5.64M is not a commercial business, it's residual/collaboration income. Putting a $4.75B market cap on that produces a P/S of 843.6x, which is not a valuation in any conventional sense — it is a probability-weighted bet on FDA approval and launch.
Sources: SEC EDGAR (CIK 0001613780, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/25/2026, 2:33:33 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $5.71M | $4.84M | $15.7M | $4.15M | $5.64M |
| Gross profit | — | — | — | — | — |
| Operating income | -$98.6M | -$96.6M | -$76.4M | -$117M | -$147M |
| Net income | -$97.8M | -$96.3M | -$72.7M | -$114M | -$147M |
| Diluted EPS | -$1.78 | -$1.24 | -$0.76 | -$1.17 | -$1.05 |
| Net margin | -1713.5% | -1987.5% | -462.4% | -2744.4% | -2607.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Officer/director change disclosed; no financial impact stated.
Annual meeting vote results and bylaw amendments approved.
Proxy for annual meeting; routine governance items.
Officer/director appointment or departure disclosed.
FY2025 10-K amendment; corrects/adds disclosures, no restatement signaled.
FY2025 10-K amendment; corrects/adds disclosures, no restatement signaled.
FY2025 10-K amendment; corrects/adds disclosures, no restatement signaled.
FY2025: $194M cash post-PIPE, positive VITESSE Phase 3 data, BLA pathway clarified.
FY2025: $194M cash post-PIPE, positive VITESSE Phase 3 data, BLA pathway clarified.
1047 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-01-29 | Mohideen Pharis Chief Medical Officer | Sell | 534.00 @ $4.86 | $2.60K |
| 2025-12-18 | EPIC Bpifrance Insider | Sell | 1.29M @ $4.19 | $5.41M |
| 2025-12-17 | EPIC Bpifrance Insider | Sell | 2.04M @ $4.84 | $9.86M |
| 2025-12-17 | EPIC Bpifrance Insider | Sell | 40.0K @ $5.28 | $211K |
| 2025-11-21 | Mohideen Pharis Chief Medical Officer | Sell | 1.62K @ $2.77 | $4.50K |
| 2025-11-21 | Mohideen Pharis Chief Medical Officer | Award | 44.0K | |
| 2025-11-21 | Boucinha Virginie Chief Financial Officer | Award | 32.0K | |
| 2025-11-21 | Trapp Kevin Michael Chief Commercial Officer | Award | 55.0K | |
| 2025-11-20 | Mohideen Pharis Chief Medical Officer | Sell | 6.50K @ $2.88 | $18.7K |
| 2025-07-29 | Mohideen Pharis Chief Medical Officer | Sell | 464.00 @ $2.22 | $1.03K |